vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and RBB Bancorp (RBB). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $32.3M, roughly 1.2× RBB Bancorp). RBB Bancorp runs the higher net margin — 31.5% vs -161.8%, a 193.3% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 12.6%). RBB Bancorp produced more free cash flow last quarter ($42.6M vs $-71.3M).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

RBB Bancorp is a US-based financial holding company that operates Royal Business Bank as its primary banking subsidiary. It caters mainly to Asian American communities, small and medium-sized enterprises, real estate investors, and retail clients, offering comprehensive commercial banking, consumer lending, deposit services, and wealth management solutions across branches in key US coastal metropolitan areas.

IBRX vs RBB — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.2× larger
IBRX
$38.3M
$32.3M
RBB
Growing faster (revenue YoY)
IBRX
IBRX
+394.4% gap
IBRX
407.0%
12.6%
RBB
Higher net margin
RBB
RBB
193.3% more per $
RBB
31.5%
-161.8%
IBRX
More free cash flow
RBB
RBB
$113.9M more FCF
RBB
$42.6M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBRX
IBRX
RBB
RBB
Revenue
$38.3M
$32.3M
Net Profit
$-61.9M
$10.2M
Gross Margin
99.0%
Operating Margin
-169.0%
39.5%
Net Margin
-161.8%
31.5%
Revenue YoY
407.0%
12.6%
Net Profit YoY
-4.7%
132.1%
EPS (diluted)
$-0.06
$0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
RBB
RBB
Q4 25
$38.3M
$32.3M
Q3 25
$32.1M
$32.6M
Q2 25
$26.4M
$35.8M
Q1 25
$16.5M
$28.5M
Q4 24
$7.6M
$28.7M
Q3 24
$6.1M
$30.3M
Q2 24
$27.5M
Q1 24
$28.2M
Net Profit
IBRX
IBRX
RBB
RBB
Q4 25
$-61.9M
$10.2M
Q3 25
$-67.3M
$10.1M
Q2 25
$-92.6M
$9.3M
Q1 25
$-129.6M
$2.3M
Q4 24
$-59.2M
$4.4M
Q3 24
$-85.7M
$7.0M
Q2 24
$7.2M
Q1 24
$8.0M
Gross Margin
IBRX
IBRX
RBB
RBB
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IBRX
IBRX
RBB
RBB
Q4 25
-169.0%
39.5%
Q3 25
-173.5%
40.7%
Q2 25
-269.8%
36.1%
Q1 25
-390.1%
11.2%
Q4 24
-919.0%
17.6%
Q3 24
-1314.3%
31.6%
Q2 24
35.6%
Q1 24
39.9%
Net Margin
IBRX
IBRX
RBB
RBB
Q4 25
-161.8%
31.5%
Q3 25
-209.8%
31.2%
Q2 25
-350.3%
26.1%
Q1 25
-784.9%
8.0%
Q4 24
-783.4%
15.3%
Q3 24
-1404.0%
23.1%
Q2 24
26.4%
Q1 24
28.4%
EPS (diluted)
IBRX
IBRX
RBB
RBB
Q4 25
$-0.06
$0.59
Q3 25
$-0.07
$0.59
Q2 25
$-0.10
$0.52
Q1 25
$-0.15
$0.13
Q4 24
$-0.08
$0.26
Q3 24
$-0.14
$0.39
Q2 24
$0.39
Q1 24
$0.43

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
RBB
RBB
Cash + ST InvestmentsLiquidity on hand
$242.8M
$212.3M
Total DebtLower is stronger
$119.9M
Stockholders' EquityBook value
$-500.5M
$523.4M
Total Assets
$501.9M
$4.2B
Debt / EquityLower = less leverage
0.23×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
RBB
RBB
Q4 25
$242.8M
$212.3M
Q3 25
$257.8M
$234.9M
Q2 25
$153.7M
$191.9M
Q1 25
$61.6M
$238.8M
Q4 24
$149.8M
$257.7M
Q3 24
$130.4M
$349.4M
Q2 24
$252.8M
Q1 24
Total Debt
IBRX
IBRX
RBB
RBB
Q4 25
$119.9M
Q3 25
$119.8M
Q2 25
$119.7M
Q1 25
$119.6M
Q4 24
$119.5M
Q3 24
$119.4M
Q2 24
$119.3M
Q1 24
$119.2M
Stockholders' Equity
IBRX
IBRX
RBB
RBB
Q4 25
$-500.5M
$523.4M
Q3 25
$-524.3M
$514.3M
Q2 25
$-570.7M
$517.7M
Q1 25
$-591.4M
$510.3M
Q4 24
$-489.1M
$507.9M
Q3 24
$-745.1M
$509.7M
Q2 24
$511.3M
Q1 24
$514.0M
Total Assets
IBRX
IBRX
RBB
RBB
Q4 25
$501.9M
$4.2B
Q3 25
$519.0M
$4.2B
Q2 25
$402.1M
$4.1B
Q1 25
$303.8M
$4.0B
Q4 24
$382.9M
$4.0B
Q3 24
$364.6M
$4.0B
Q2 24
$3.9B
Q1 24
$3.9B
Debt / Equity
IBRX
IBRX
RBB
RBB
Q4 25
0.23×
Q3 25
0.23×
Q2 25
0.23×
Q1 25
0.23×
Q4 24
0.24×
Q3 24
0.23×
Q2 24
0.23×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
RBB
RBB
Operating Cash FlowLast quarter
$-70.4M
$43.4M
Free Cash FlowOCF − Capex
$-71.3M
$42.6M
FCF MarginFCF / Revenue
-186.2%
131.8%
Capex IntensityCapex / Revenue
2.4%
2.5%
Cash ConversionOCF / Net Profit
4.26×
TTM Free Cash FlowTrailing 4 quarters
$-308.8M
$73.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
RBB
RBB
Q4 25
$-70.4M
$43.4M
Q3 25
$-68.9M
$2.1M
Q2 25
$-79.7M
$21.7M
Q1 25
$-85.9M
$7.8M
Q4 24
$-85.1M
$58.5M
Q3 24
$-98.8M
$24.5M
Q2 24
$11.7M
Q1 24
$4.8M
Free Cash Flow
IBRX
IBRX
RBB
RBB
Q4 25
$-71.3M
$42.6M
Q3 25
$-69.6M
$1.8M
Q2 25
$-80.8M
$21.6M
Q1 25
$-87.0M
$7.6M
Q4 24
$-87.3M
$57.7M
Q3 24
$-101.6M
$24.2M
Q2 24
$11.5M
Q1 24
$4.7M
FCF Margin
IBRX
IBRX
RBB
RBB
Q4 25
-186.2%
131.8%
Q3 25
-217.2%
5.4%
Q2 25
-305.9%
60.2%
Q1 25
-526.9%
26.7%
Q4 24
-1155.4%
201.0%
Q3 24
-1663.2%
80.0%
Q2 24
42.0%
Q1 24
16.6%
Capex Intensity
IBRX
IBRX
RBB
RBB
Q4 25
2.4%
2.5%
Q3 25
2.3%
1.1%
Q2 25
4.1%
0.3%
Q1 25
6.8%
0.6%
Q4 24
28.0%
2.7%
Q3 24
45.7%
0.8%
Q2 24
0.5%
Q1 24
0.5%
Cash Conversion
IBRX
IBRX
RBB
RBB
Q4 25
4.26×
Q3 25
0.21×
Q2 25
2.32×
Q1 25
3.39×
Q4 24
13.34×
Q3 24
3.50×
Q2 24
1.61×
Q1 24
0.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons